A province-level risk factor analysis of fluoroquinolone consumption patterns in Canada (2000-06)
Open Access
- 24 June 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 65 (9), 2019-2027
- https://doi.org/10.1093/jac/dkq225
Abstract
To assess potential risk factors among socioeconomic variables and the rate of influenza for the use of different fluoroquinolone antimicrobials in Canada, and to evaluate modelling fluoroquinolone-use data by two different outcome measures. Fluoroquinolone use was described monthly from 2000 to 2006 by two outcome measurements: defined daily doses and prescription counts. Multivariable linear and negative binomial models were produced with socioeconomic and influenza rate data. Significant socioeconomic predictors varied among the individual fluoroquinolone models, which may reflect the range of infections that are treated with fluoroquinolones. However, socioeconomic variables within the ciprofloxacin and levofloxacin models were similar, and indicated that use was highest in advantaged populations, depending on the measures being assessed. The rate of influenza was a significant predictor within models describing levofloxacin use and the defined daily dose model for ciprofloxacin use, after accounting for season. Influenza significantly interacted with the education variable in the levofloxacin defined daily dose model. Significant associations between levofloxacin use and influenza rates, after accounting for season, may suggest that levofloxacin was used to treat secondary bacterial infections or was prescribed inappropriately for seasonal viral respiratory tract infections. Yearly patterns of ciprofloxacin use show that prescribing practices changed; more ciprofloxacin prescriptions were dispensed towards the end of the study period, but for smaller doses or shorter treatment times. Associations with socioeconomic variables suggest that the fluoroquinolones ciprofloxacin and levofloxacin were more likely to be used in advantaged populations, probably due to the high cost of fluoroquinolone antimicrobials in comparison to the penicillin and macrolide groups.Keywords
This publication has 26 references indexed in Scilit:
- Canadian province-level risk factor analysis of macrolide consumption patterns (2000-2006)Journal of Antimicrobial Chemotherapy, 2009
- Antibiotic use and population ecology: How you can reduce your "resistance footprint"CMAJ : Canadian Medical Association Journal, 2009
- Fluoroquinolones and Risk for Methicillin-ResistantStaphylococcus aureus, CanadaEmerging Infectious Diseases, 2006
- The use of fluoroquinolones in childrenCurrent Opinion in Pediatrics, 2006
- A Review of Streptococcus pneumoniae Infection Treatment Failures Associated with Fluoroquinolone ResistanceClinical Infectious Diseases, 2005
- Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United StatesDiagnostic Microbiology and Infectious Disease, 2005
- Predicting Hospital Rates of Fluoroquinolone-Resistant Pseudomonas aeruginosa from Fluoroquinolone Use in US Hospitals and Their Surrounding CommunitiesClinical Infectious Diseases, 2004
- A Critical Review of the FluoroquinolonesDrugs, 2002
- Urinary tract infection among women aged 40 to 65Journal of Clinical Epidemiology, 2001
- Phenotypic Resistance of Staphylococcus aureus , Selected Enterobacteriaceae , and Pseudomonas aeruginosa after Single and Multiple In Vitro Exposures to Ciprofloxacin, Levofloxacin, and TrovafloxacinAntimicrobial Agents and Chemotherapy, 2001